Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices

Reuters

03/11

<a href="https://laohu8.com/S/FEMY">Femasys Inc</a>. Publishes Corporate Presentation on Women’s Reproductive Health Devices

Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and New Zealand, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2618095211"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618095211\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618095211?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618095211","market":"nz","top_or_hot":-1,"title":"Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FEMY\">Femasys Inc</a>. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a>, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFemasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-11 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FEMY\">Femasys Inc</a>. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a>, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL730kY9:1","article_id":"2618095211","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618095211","pubTimestamp":1773158955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and New Zealand, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4082":"医疗保健设备","BK4539":"次新股","FEMY":"Femasys Inc"},"translate_title":"Femasys Inc.发布有关女性生殖健康设备的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FEMY":0.9},"content_text":"Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n    \n\n        Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and New Zealand, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}